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Synopsis 
 
Selenium (Se) is an unusual trace element in having its own codon in mRNA that specifies its 
insertion into selenoproteins as selenocysteine (Sec), by means of a mechanism requiring a 
large Sec-insertion complex.  This exacting insertion machinery for selenoprotein production 
has implications for our Se requirements for cancer prevention.  If Se may protect against 
cancer, an adequate intake of Se is desirable.  However, the level of intake in Europe and 
some parts of the world is not adequate for full expression of protective selenoproteins. The 
evidence for Se as a cancer preventive agent includes that from geographic, animal, 
prospective and intervention studies.  Newly-published prospective studies on oesophageal, 
gastric-cardia and lung cancer have reinforced previous evidence which is particularly strong 
for prostate cancer.  Interventions with Se have shown benefit in reducing the risk of cancer 
incidence and mortality in all cancers combined, and specifically in liver, prostate, colorectal 
and lung cancers.  The effect seemed to be strongest in those with the lowest Se status. As the 
level of Se that appears to be required for optimal effect is higher than that previously 
understood to be required to maximise the activity of selenoenzymes, the question has been 
raised as to whether selenoproteins are involved in the anti-cancer process.  However, recent 
evidence showing an association between Se, reduction of DNA damage and oxidative stress 
together with data showing an effect of selenoprotein genotype on cancer risk implies that 
selenoproteins are indeed implicated.  The likelihood of simultaneous and consecutive effects 
at different cancer stages still allows an important role for anti-cancer Se metabolites such as 
methyl selenol formed from γ-glutamyl-selenomethyl-selenocysteine and selenomethyl-
selenocysteine, components identified in certain plants and Se-yeast that have anti-cancer 
effects.  There is some evidence that Se may affect not only cancer risk but also progression 
and metastasis.  Current primary and secondary prevention trials of Se are underway in the 
USA including the SELECT prostate cancer trial, though a large European trial is still 
desirable given the likelihood of a stronger effect in populations of lower Se status. 
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Selenium (Se) is an essential trace element like no other.  Its unique redox chemistry has been 
exploited by biological systems since the advent of dioxygen in the earth's environment 
created a requirement for a two-electron detoxification system for dealing with peroxides (da 
Silva & Williams, 2001).  Its crucial role is underlined by the fact that it is the only trace 
element to be specified in the genetic code (Prof. RJP Williams, personal communication, 
1999) - as selenocysteine (Sec), the 21st amino acid - which when incorporated into 
selenoproteins, protects tissues and membranes from oxidative stress and controls cell redox 
status (Rayman, 2000).  As we shall see later, Sec is "dramatically different from the other 20 
amino acids in the mode of its incorporation and basic biosynthetic steps" (Hatfield & 
Gladyshev, 2002) and this complex insertion machinery for selenoprotein production has 
implications for our Se requirements for cancer prevention.  
 
Evidence is accruing, some of which will be presented below, that the level of intake of Se 
affects the risk of cancer and may even inhibit its spread from a primary tumour.  Since UK 
deaths from cancer in adults now outnumber those from ischaemic heart disease and stroke 
and around one in three people in Europe will be diagnosed with cancer during their lifetime 
(CancerStats, 2004a, b), it is timely to consider the potential of Se for cancer reduction.  
 
The nature of the Se species involved in anti-cancer processes is still a matter of speculation 
and much ongoing experimental work.  Whether the selenoproteins are crucial to the anti-
cancer effects requires some understanding of the biosynthetic machinery involved and of the 
function of some of the selenoproteins most likely to be relevant to cancer.  These issues will 
be addressed in the following section. 
 
 
 
Selenoproteins 
 
Biosynthesis 
 
Unlike the other 20 amino acids, Sec is biosynthesised on its own tRNA, Sec tRNA[Ser]Sec, 
from selenophosphate as the Se source.  Sec tRNA[Ser]Sec has many unusual features including 
its long length (Hatfield & Gladyshev, 2002).  The insertion of Sec is specified by the UGA 
codon in mRNA.  However, as UGA is also a stop codon, the presence of a stem-loop 
structure in mRNA - a SECIS (Sec Insertion Sequence) element - downstream from UGA in 
the 3′-mRNA-untranslated region, is also required for UGA to be read as selenocysteine.  
SECIS elements function by recruiting additional factors including the SECIS-binding 
protein, the Sec-specific elongation factor and Sec tRNA[Ser]Sec, to form the large Sec 
insertion complex required for the synthesis of selenoproteins and known as the selenosome 
(Berry et al. 1991, 1993; Hatfield & Gladyshev, 2002).  The human selenoproteome consists 
of 25 selenoproteins (Kryukov et al. 2003).    
 
 
 
Some selenoproteins of particular relevance to cancer 
 
The functions of many of the 25 human selenoproteins are as yet unknown though they 
generally participate in antioxidant and anabolic processes (Hatfield & Gladyshev, 2002).  
Selenoproteins that may be relevant to cancer risk are described in Table 1 and include a 
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number from the glutathione peroxidase family (GPx), the 15kDa selenoprotein (Sep15), 
selenoprotein P (SelP), and the thioredoxin reductases (TR) though a beneficial role of the 
TRs in cancer prevention is questionable.  
 
 
 
Selenium intakes and status of adults in different countries 
 
If Se may protect against cancer, an adequate intake of Se is desirable.  Whether the intake of 
Se is adequate is however questionable in much of Europe and some other parts of the world. 
Mean intake levels in a number of countries (Combs, 2001; Rayman 2004) are shown in 
Figure 1 which also indicates the range of Se intake believed to be required for optimal 
activity of plasma GPx (Thomson et al. 1993, Duffield et al. 1999).  It is clear from this 
figure that the level of intake in Europe and some parts of China is not adequate for full 
expression of GPx.  [According to Combs (2001), the same may be true of other parts of the 
world, as there is little or no information on Se intake or status for most of Africa, South 
America and central and south Asia.]  Furthermore, an updated study of Se requirements by 
Burk’s group in collaboration with Chinese colleagues (Xia et al. 2005), has shown that full 
expression of selenoprotein P requires a greater selenium intake than does full expression of 
plasma GPx.  Thus it is even more likely that current intakes are inadequate for optimizing 
protective effects of the selenoproteins.  Indeed there is evidence that will be outlined below, 
that levels of Se intake that are supra-nutritional may be required to reduce cancer risk 
(Combs, 2001; Rayman, 2002). 
   
 
 
Evidence for an effect of Se on cancer risk 
 
The evidence for selenium as a cancer preventive agent has been reviewed ably by a number 
of people including Combs and Grey (1998), Ip (1998), Combs and Lü (2001), Knekt (2002) 
Whanger (2004) and Combs (2005).   It includes findings from in vitro, animal, geographic 
(ecological) and prospective studies and from interventions with Se.  Such evidence will be 
summarised and updated below though in vitro studies and those on Se-compounds that 
cannot arise from food sources will only be referred to in passing: interested readers are 
referred to the references above.  Case-control studies will be excluded as it is not possible to 
distinguish between selenium concentration as an indicator of cancer risk and that which is a 
consequence of the disease process (Overvad 1998). 
 
 
Animal studies 
 
Extensive experimental evidence indicates that selenium supplementation reduces the 
incidence of cancer in animals (Combs & Gray 1998; Combs & Lü 2001; Medina, & 
Morrison 1988).  However, it is difficult to generalise from such studies to the human 
situation, as animal studies have generally used doses at least ten times greater than those 
required to prevent clinical signs of deficiency, which, on a per unit body-weight basis, are 
considerably higher than most human Se intakes.  However, it is worth describing a 
supplementation study on male beagle dogs, a species that develops spontaneous prostate 
cancer, as the lower dose given is reasonable for humans.  Supplementation of the diet of 
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sexually intact elderly male dogs with selenium as selenomethionine or high-selenium yeast 
at 3 or 6 µg/kg body weight per day for seven months, significantly reduced DNA damage 
and significantly upregulated epithelial-cell apoptosis in their prostates while no such effects 
were seen in unsupplemented dogs (Waters et al. 2003).  It appears that selenium sensitises 
prostate epithelial cells so that cells with extensive DNA damage undergo apoptosis in vivo.  
 
 
Geographic (ecological) studies 
 
Since as early as the 1960s, geographic studies have shown a consistent trend for populations 
with low selenium intakes to have higher cancer mortality rates (Shamberger & Frost 1969; 
Schrauzer et al. 1977; Clark et al. 1991).   In one such study (Schrauzer et al. 1977), 
significant inverse correlations were observed between apparent dietary selenium intakes 
estimated from food-consumption data in 27 countries, and age-corrected mortality for a 
number of cancers, including that of the prostate.  However, the value of evidence from this 
type of study is not rated very highly by epidemiologists. 
   
 
Prospective and nested case-control studies 
 
Knekt (2002) has tabulated the results of prospective studies of Se and cancer published up 
the end of 1998.  The following categories were included:- all cancers; lung cancer; 
colorectal, gastrointestinal and stomach; prostate cancer; female cancers and miscellaneous 
cancers that included cancers of the liver, bladder, mouth, pharynx, oesophagus and 
malignant melanoma.  Of approximately 72 table entries, 50 showed a lower risk associated 
with higher Se intake or status though only in 18 studies (25%) that included all cancers, 
cancers of the bladder, lung, ovary, prostate, stomach and thyroid, was the risk significantly 
reduced. 
 
More recent evidence that Se status can influence mortality from all cancers combined has 
recently been found in a cohort of 1389 male and female volunteers recruited in the Etude du 
Vieillissement Artériel (EVA) study (Akbaraly et al. in press).  Mean baseline plasma Se in 
the cohort was 86 µg/L, similar to levels in much of Europe.  During the 9-year follow-up, 
101 subjects died, 45 of them from cancer.  The risk of mortality from cancer was increased 
four-fold in subjects in the bottom quartile of baseline plasma Se compared to those in the top 
quartile (Relative Risk, RR = 4.06; 95% Confidence Interval, CI 1.51; 10.92, p = 0.006).   
 
The strongest evidence for a beneficial effect of Se from prospective studies appears to relate 
to lung cancer, oesophageal and gastric-cardia cancers and most notably to prostate cancer.  
The risk of colorectal adenoma, a pre-cancerous condition, also seems to be affected. 
 
Lung Cancer  
A recent meta-analysis of existing epidemiological evidence from 16 studies showed a 
significantly decreased risk of lung cancer (summary RR 0.74) associated with higher Se 
exposure (Zhuo et al. 2004; Table 3).  The effects occurred primarily in populations of low 
Se exposure (defined as serum Se < 100 µg/L or intake < 55 µg/d).  In studies carried out in 
high-Se areas (defined as serum Se > 100 µg/L or intake > 55 µg/d), protective effects 
appeared on moving from the lowest to the second-lowest Se category but increasing Se 
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exposure thereafter appeared to have little further effect, suggesting the existence of a 
threshold effect. 
 
Oesophageal cancer and gastric cardia cancer  
In a nested study from the Nutrition Intervention Trial in Linxian, China, significant inverse 
associations were found between baseline serum Se concentration as a continuous variable 
and death from oesophageal squamous cell carcinoma (RR 0.83; 95% CI 0.71, 0.98) and 
gastric cardia cancer (RR 0.75; 95% CI 0.59, 0.95) in 1103 subjects randomly-selected from 
the larger trial cohort and followed for 15 years (Wei et al. 2004).  When the subjects were 
classified by quartile of baseline Se, those in the highest quartile had a 65% significant 
reduction in the risk of death from oesophageal squamous cell carcinoma (RR 0.35; 95% CI 
0.16, 0.81) and a 69% significant reduction in the risk of death from gastric cardia cancer 
(RR 0.31; 95% CI 0.11, 0.87) when compared with those in the lowest quartile.  The mean 
population serum Se concentration in the cohort, at 73 µg/L, was relatively low.  The authors 
have suggested that population-wide Se supplementation in regions of China with low serum 
Se and high rates of these cancers merits serious consideration (Wei et al. 2004).  
 
Prostate Cancer  
Results of large prospective studies of prostate cancer are shown in Table 2 (Knekt et al. 
1990, Yoshizawa et al. 1998; Nomura et al. 2000; Helzlsouer et al. 2000; Goodman et al. 
2001; Brooks et al. 2001, van den Brandt et al. 2003, Li et al. 2004).  Those published in 
2003 and 2004 are large studies having 540 (van den Brandt et al. 2003) and 586 (Li et al. 
2004) cases.  Of the eight prospective studies listed, seven show a reduced risk of prostate 
cancer overall for the highest versus lowest category of Se status, the risk being significantly-
reduced in five.  When analysis is confined to subjects with advanced prostate cancer or 
baseline prostate specific antigen (PSA) > 4, six of the eight prospective studies show a 
significant reduction in prostate cancer in those in the highest category of Se status.   
 
Though the study of Knekt and colleagues (1990) in Finland showed no relation between 
serum Se concentration and prostate cancer risk, as pointed out by Platz and Helzlsouer 
(2001), participants had circulating levels almost three-times lower than in the other studies 
(around 50 vs. 150 µg/L).   Thus it may be possible that the concentration of selenium in this 
cohort was below the threshold where Se can exert a protective effect on prostate cancer risk.  
This possibility is given credence by the study of Nomura et al. (2000) that showed the 
protective effect (Odds Ratio, OR 0.5) mainly in persons with serum Se >147 µg/L with ORs 
close to 1 in lower quartiles of plasma Se.   
 
In a number of these studies (Yoshizawa et al. 1998; Nomura et al. 2000; van den Brandt et 
al. 2003, Li et al. 2004), the protective effect of Se was stronger for advanced prostate cancer 
i.e. disease that has spread beyond the prostate, than for localised disease.  Furthermore, 
when data from the Physicians' Health Study were analysed according to baseline PSA level, 
the protective effect was significant for all prostate cancers  (both localised and advanced 
disease) but only in those with baseline PSA > 4 (Li et al. 2004), again suggesting a major 
effect of Se on prostate cancer progression rather than initiation.  
 
Two studies suggested that smoking modifies the effect of Se: the Netherlands Cohort Study 
showed by far the strongest effect of Se in ex-smokers (van den Brandt et al. 2003) while the 
inverse association between Se and prostate cancer was mainly present in current or past 
cigarette smokers in the study of Nomura and colleagues (2000). 
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Colorectal adenoma  
Colorectal adenoma is closely associated with subsequent development of colorectal cancer 
(Weingarten et al. 2005).  Jacobs and colleagues (2004) carried out a pooled analysis of data 
from three studies that could be considered as prospective studies of Se and risk of colorectal 
adenoma.  The Wheat Bran Fiber Trial, the Polyp Prevention Trial and the Polyp Prevention 
Study were 3-4-year interventions in subjects that had recently undergone adenoma removal, 
1763 of whom had baseline serum or plasma Se measured.  None of the trials affected the 
risk of adenoma recurrence.  Analysis of pooled data showed that those with baseline serum 
or plasma Se in the  highest quartile (median 150 µg/L), when compared with those in the 
lowest quartile (median 113 µg/L), had significantly lower risk of adenoma recurrence (OR 
0.66; 95% CI 0.50, 0.87).  These results support previous findings that are suggestive of a 
beneficial effect of higher Se status on colorectal cancer risk (Jacobs et al. 2004). 
 
 
Intervention studies including randomised controlled trials 
 
Chinese trials  
NCI sponsored trials in China for the prevention of oesophageal and gastric cancer observed 
a reduction in total cancer mortality and a significantly reduced incidence of oesophageal and 
gastric-cardia cancers in the intervention arm containing Se, β-carotene, and vitamin E (Blot 
et al 1993; Mark et al. 2000).  Though Se was not a single agent in these trials, it is likely to 
have been the most effective component particularly in the light of subsequent studies (Wei et 
al. 2004).  [As one of a number of agents in an Indian trial, Se also aided remission of pre-
cancerous lesions of the oral cavity (Krishnaswamy et al. 1995; Prasad et al. 1995).] 
 
Hepatocellular carcinoma (HCC) is highly prevalent in China.  In the Qidong county, near 
Shanghai, its incidence is particularly high.  In this region around 15% of adults carry the 
Hepatitis B surface antigen and these people are 200 times more likely to develop HCC.  In a 
study where 226 Hepatitis B antigen carriers were randomised to either 200 µg of Se-yeast or 
placebo, no case of HCC occurred in the supplemented group after four years, while seven 
subjects in the placebo group had developed HCC (Yu et al. 1997).  However, as full details 
of the methodology of this study are not available, it is difficult to assess whether its protocol 
was sufficiently well-controlled or robust to be confident in its conclusions.   
 
A recent systematic review and meta-analysis of antioxidant supplements for the prevention 
of gastrointestinal cancers has assessed the evidence for an effect of Se (Bjelakovic et al. 
2004).  Data from three Chinese trials were included two of which used Se-yeast (Yu et al. 
1997), while one used sodium selenite (Li et al. 2000).  Bjelakovic and colleagues concluded 
that, in contrast to other antioxidant nutrients, Se showed a significant beneficial effect, 
reducing the risk of HCC by 50% (RR 0.50; 95% CI 0.35, 0.71).  
 
The Nutritional Prevention of Cancer (NPC) Trial and follow-up analyses 
The strongest evidence of the efficacy of Se as an anti-cancer agent, particularly for prostate 
cancer, is provided by the Nutritional Prevention of Cancer (NPC) trial, carried out by Clark 
and co-workers (Clark et al. 1996; Clark et al. 1998).  In 1312 subjects with a history of non-
melanoma skin cancer who were randomised to placebo or 200 µg Se/day (as Se-enriched 
yeast), after 4½ years of treatment and 6½ years of follow-up, there was no effect on the 
primary end-point of non-melanoma skin cancer.  However, those receiving Se showed 
significant secondary end-point effects of 50% lower total cancer mortality and 37% lower 
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total cancer incidence with fewer cancers of the prostate, colon/rectum and lung (Table 4).  
Follow-up analyses to the end of the blinded treatment period - a further 25 months - showed 
a somewhat-reduced significant effect on total cancer but while the protective effect on 
prostate cancer remained highly-significant, the effect on lung and colorectal cancers no 
longer reached significance (Duffield-Lillico et al. 2002; Table 4).   
 
Although follow-up analyses confirmed initial findings that Se supplementation was not 
statistically significantly associated with the incidence of basal-cell carcinoma (Cox 
proportional hazards model, Hazard Ratio, HR 1.09; 95% CI 0.94, 1.26), the extended 
treatment period raised the elevated risk of squamous-cell carcinoma and total non-melanoma 
skin cancer to statistically-significant levels (HR 1.25; 95% CI 1.03, 1.51 and HR 1.17; 95% 
CI 1.02, 1.34 respectively)  (Duffield-Lillico et al. 2003a).  However there are a number of 
reassuring factors that are relevant here:- firstly, when a treatment lag of two years following 
randomisation was introduced, thus excluding lesions already in the course of development, 
the significant effect disappeared; secondly, when subjects were divided into tertiles 
according to baseline Se status, those in the bottom tertile (see above), whose status 
resembled that found in Europe, did not have an increased risk of squamous-cell carcinoma 
(HR 0.87; 95% CI 0.62, 1.22).  Finally it must be remembered that the subjects in the NPC 
Trial were all skin-cancer patients whose skin had sustained heavy sun-damage (Duffield-
Lillico et al. 2003a). 
 
The Nutritional Prevention of Cancer (NPC) Trial sub-group analyses  
The protective effect of Se was confined to men both in the initial and follow-up analyses, 
though the fact that there were many fewer women than men (319 vs. 931) must be taken into 
consideration (Clark et al. 1996; Duffield-Lillico et al. 2002).  As seen in some of the 
prospective studies quoted above, the protective effect of Se was stronger in former smokers 
(Duffield-Lillico et al. 2002).  
 
Analysis of treatment effect in the NPC trial by initial plasma Se status, showed that the 
strongest treatment effect was observed in subjects in the lowest tertile of plasma Se at 
baseline i.e. those whose plasma Se concentration was <106 µg/L at entry to the trial 
(Duffield-Lillico et al. 2002).  Se supplementation reduced total cancer incidence in this 
tertile by 49% (HR 0.51; 95% CI 0.32, 0.81) (Duffield-Lillico et al. 2002) and prostate cancer 
incidence by 86% (HR = 0.14; 95% CI 0.03, 0.61) (Duffield-Lillico et al. 2003b) in the 
follow-up analyses.  Most UK and European populations would fall into this tertile. 
 
A significant interaction between baseline plasma Se and treatment was detected such that 
those in the top tertile (>121.6 µg/L) that were supplemented with Se had a significantly 
increased risk of total cancer (HR 1.88; 95% CI 1.15, 3.05; P=0.01) (Duffield-Lillico et al. 
2002).  Though this is a sub-group analysis of a secondary end-point analysis and must 
therefore be regarded with caution, it does raise queries about the advisability of 
supplementing individuals of already-adequate status (say 120 µg/L or more) with Se.  
 
 
Insights from the evidence presented 
 
What lessons can we learn from the NPC Trial?  It would appear that plasma Se should reach 
around 120 µg/L to optimise the anti-cancer effect of Se.  This is higher than the level 
previously understood to be required to maximise the activity or concentration of 
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selenoenzymes such as GPx (Thomson et al. 1993; Duffield et al. 1999) though we have 
recently had to revise our ideas upwards on this as a result of new findings on requirements 
for selenoprotein P (Xia et al. 2005).  Does this mean that the selenoenzymes are not relevant 
to the anti-cancer effects of Se or do some individuals have a higher Se requirement, perhaps 
as a result of single-nucleotide polymorphisms (SNPs) in their selenoprotein genes?  This 
issue will be addressed as part of a general consideration of possible mechanisms by which 
Se may reduce cancer risk. 
 
 
 
Se anticancer mechanisms 
 
A number of mechanisms have been suggested to explain the anti-cancer effects of Se.  These 
are summarised in Table 5 together with explanatory references.    Though there is fairly 
general acceptance that methyl selenol is involved in the anti-cancer effects of Se at supra-
nutritional doses as explained below, evidence is accruing, some from effects of functional 
selenoprotein polymorphisms, that the selenoenzymes do play a role, particularly at 
nutritional levels of intake.  Se in selenoproteins can reduce oxidative stress and limit DNA 
damage both of which have been linked to cancer risk. Some of these anti-cancer processes or 
pathways are discussed more fully below. 
 
 
Methyl selenol and its precursors 
 
The in vivo production of small-molecular weight Se metabolites such as methyl selenol 
(CH3SeH) that have potent anti-cancer properties has been inferred from work carried out by 
a number of research groups (Ip,1998; Ip et al. 2000, 2002; Jiang et al. 1999; Davis & Finley, 
2003; Spallholz et al. 2004; Whanger, 2004).  The metabolism of dietary forms of Se is 
shown in Figure 2 (adapted from Combs, 2001 and Rayman, 2004) from which it can be seen 
that methyl selenol can be formed by the methylation of hydrogen selenide as part of the Se 
excretory pathway.  There is also some evidence that methyl selenol can be formed directly 
from selenomethionine (SeMet) either by the action of a γ-lyase, also known as methioninase 
(Nakamuro et al. 1997; Spallholz et al. 2004; Wang et al. 2002) or by an α,γ-elimination 
reaction (Okuno et al. 2005).  Alternatively it can be formed from a storage form of Se, 
namely γ-glutamyl-Se-methyl-Se-cysteine (γ-glutamyl-SeMeSeCys), that is present in plants 
of the Brassica and Allium families (Ip et al. 2000; Kotrebai et al. 2000; Whanger, 2004) and 
probably accounts for the anti-tumour effects of Se-enriched broccoli and garlic (Ip et al. 
2000; Davis & Finlay 2003).  Metabolism removes the γ-glutamyl group to give Se-methyl-
Se-cysteine (SeMeSeCys) which is acted upon by a β-lyase to give methyl selenol directly (Ip 
et al. 2000; Combs, 2001).  There is a suggestion that the β-lyase is present at a higher level 
in cancer cells than normal cells, ensuring greater exposure of the tumour cells to the anti-
cancer agent (Spallholz et al. 2004).    
 
Speciation studies have been carried out on Se-enriched yeast (Se-yeast), the form of Se 
shown to be effective in most human interventions.  These have shown the presence of small 
amounts of both γ-glutamyl-SeMeSeCys and SeMeSeCys, dependent on the method of 
extraction, inferring that methyl selenol may be produced directly from the Se-yeast without 
the necessity of conversion from SeMet, its major Se constituent (Goenaga Infante et al. 
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2004, 2005).  As SeMeSeCys was more than twice as effective as SeMet in reducing 
mammary tumours in rats (Whanger, 2004), even these small amounts may be important.   
 
Precursors of methyl selenol, typically methyl seleninic acid (CH3SeO2H) in experimental in 
vitro systems, have been shown to block progression of the cell cycle, induce apoptosis of 
cancer cells and inhibit the formation of new blood vessels, without which tumours cannot 
grow or metatasise (Ip, 1998; Jiang et al. 1999; Ip et al. 2000; Davis & Finley, 2003; 
Whanger, 2004).  Processes by which these effects are achieved may involve redox cycling 
linked to oxidative-stress-induced apoptosis as described by Spallholz and colleagues (2004) 
and include changes in the expression of genes that control the cell-cycle checkpoint, regulate 
signalling pathways and caspase-mediated apoptosis (Dong et al. 2003).  For instance, 
SeMeSeCys activates caspase-3 in mouse mammary epithelial tumor cells in vitro (Unni et 
al. 2001) while methyl seleninic acid is known to activate initiator caspases-1, 8, 10, and 12 
(Zu & Ip, 2003).  Apoptosis induced by methyl seleninic acid in DU-145 and PC-3 human 
prostate cancer cells is principally initiated by caspase-8 and involves cell detachment as a 
pre-requisite (Jiang et al. 2001; Zu & Ip, 2003).  Caspase-12, an endoplasmic reticulum (ER)-
resident caspase essential for ER stress-induced apoptosis, is also activated during apoptosis 
induced by methyl seleninic acid in PC-3 cells, suggesting a possible role for ER stress in 
apoptosis induced by methyl selenol (Zu & Ip, 2003).  
 
 
Reduction of DNA damage 
 
Evidence that Se can reduce DNA damage comes from studies in dogs and humans.  In a 
canine model of prostate cancer, 49 elderly male beagle dogs, physiologically equivalent to 
62-69 year old men and similarly subject to prostate cancer, received nutritionally adequate 
or supra-nutritional levels of dietary Se as SeMet or Se-yeast for 7 months (Waters et al. 
2005).  DNA damage in the prostate was measured by the alkaline comet assay while Se was 
measured in toenails.  The percentage of prostate cells with extensive DNA damage fell with 
increased Se exposure up to a level of 0.8-0.9 µg/g, as measured in dog toenails.  Above 1.0 
µg/g toenails, damage began to rise, demonstrating the typical U-shaped response to a 
nutrient that is toxic at high levels.  Though the authors claim to have supplemented the dogs 
over the range of intake seen in US men, the baseline maintenance diet, at 0.3 ppm Se, gave 
an intake in the control group of 6 µg/kg body-weight, already equivalent to a high human 
intake i.e. 450 µg/d for a 75 kg man.  The highest supplement level was an additional 6 µg 
Se/kg body-weight, equivalent to a total daily intake of 900 µg/d for a 75 kg man.  It is 
therefore not surprising that the upward arm of the U was breached. 
 
In a New Zealand study of men aged 50-75 y at risk of prostate cancer (PSA > 4), the comet 
assay showed a significant inverse relationship with overall accumulated DNA damage (p = 
0.02) in blood leukocytes from those with serum Se below the mean (Karunasinghe et al. 
2004).  As mean serum Se was measured as 98 ± 17 µg/L, this suggests that serum levels 
above 98 µg/L are required for the prevention of DNA damage in New Zealand men. 
 
Women born with a BRCA1 mutation carry a lifetime risk of breast cancer of 80% and a 
lifetime risk of ovarian cancer of 40% (Kowalska et al. 2005).  The BRCA1 gene product is 
involved in maintaining the integrity of the human genome and helps repair double-strand 
breaks.  When blood lymphocytes from BRCA1 carriers are exposed to bleomycin, a known 
mutagen that induces double-strand breaks, an increased frequency of chromosome breaks 
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per cell occurs i.e. 0.58 in BRCA1 carriers vs. 0.39 in non-carriers (Kowalska et al. 2005).   
In 32 female BRCA1 carriers supplemented with Se (276 µg/d as sodium selenite) for 1-3 
months, the frequency of chromosome breaks was significantly reduced from 0.63 per cell 
before supplementation with Se to 0.40 per cell after supplementation with Se, bringing it to 
the level in non-carrier controls.  Thus Se may have the potential to reduce breast-cancer risk 
in these women.  
 
Reduction of oxidative stress 
 
That the ability of Se in selenoproteins to reduce oxidative stress is relevant to its anti-cancer 
effects is suggested by the modification of these effects by other antioxidant nutrients.  Thus 
Se intake or status becomes more important when the concentration of other antioxidants or 
activity of other antioxidant enzymes is low.  The strongest effect of Se on cancer risk has 
been shown among those with the lowest levels of dietary antioxidant vitamins and 
carotenoids (Willett et al. 1983; Kok et al. 1987; Salonen et al. 1985; Knekt et al. 1990; van 
den Brandt et al. 1993, 2003; Yu et al. 1999) and particularly at low α-tocopherol 
concentrations (Combs & Gray, 1998).  In the study of Yoshizawa and colleagues (1998) 
summarised in Table 2, the inverse association between Se status and advanced prostate 
cancer was slightly stronger after excluding men with an intake of vitamin E that exceeded 30 
IU/d, mostly from supplementary sources (OR = 0.29 vs. 0.35).  Data as yet unpublished 
from the NPC Trial show that the effect of Se supplementation on prostate cancer risk only 
reached significance in subjects in the bottom half of α-tocopherol status (p = 0.03 vs. 0.31 in 
the top half; Dr. Mary Reid, personal communication, 2005).  
  
A further indication of a link between the antioxidant capacity of Se and cancer risk is seen in 
the modification of that Se-dependent risk by a polymorphism in manganese superoxide 
dismutase (MnSOD), the primary antioxidant enzyme in mitochondria.  MnSOD has a valine 
(V) to alanine (A) polymorphism at codon 16 in the mitochondrial targeting sequence that 
affects the structure of the protein.  The relationship between prostate cancer, the MnSOD 
polymorphism and baseline plasma Se concentration was investigated in 567 cases and 764 
controls nested within the prospective Physicians’ Health Study (Li et al. 2005).  Though 
there was little overall association between MnSOD polymorphism and prostate cancer risk, 
in men with the A/A genotype, high Se status (4th vs. 1st quartile) was associated with a 
significantly lower risk (RR 0.3; 95% CI 0.2, 0.7, p for trend = 0.002).  For clinically-
aggressive prostate cancer, the relative risk was even more reduced (RR 0.2; 95% CI 0.1, 0.5, 
p for trend < 0.001).  In contrast, in men with one or two V alleles, the relative risk in the 4th 
compared to the 1st quartile was less affected by Se status (RR 0.6; 95% CI 0.4, 1.0 and RR 
0.7; 95% CI 0.4, 1.2) for total and clinically-aggressive prostate cancer respectively (Li et al. 
2005).  The interdependence of MnSOD, Se status and prostate-cancer risk implies a role for 
the antioxidant selenoenzymes. 
 
 
Evidence for a role of selenoproteins in cancer prevention from selenoprotein 
genotype data 
 
It had been thought that selenoenzymes were not involved in anti-cancer mechanisms because 
the amount of Se supplemented that reduced cancer risk (200µg/d) was significantly greater 
than the amount then believed to be needed to optimise selenoenzyme activity (Combs & 
Gray, 1998).  However, it has recently become clear that optimal expression of some 
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selenoproteins, notably selenoprotein P, requires a higher amount, as yet undetermined, of 
dietary Se (Xia et al. 2005), and furthermore that a substantial number of individuals may 
have a higher requirement for Se for efficient synthesis of selenoproteins as explained below.   
 
People differ substantially in their ability to increase selenoprotein activity in response to 
additional dietary Se (Brown et al. 2000).  This inter-individual variation in selenoprotein 
expression levels may be accounted for by SNPs in selenoprotein genes that determine the 
efficiency with which individuals can incorporate selenium into selenoproteins (Hu et al. 
2001; Hu & Diamond, 2003; Kumaraswamy et al. 2000; Ratnasinghe et al. 2000).  Thus 
requirements for dietary selenium for optimal protection against cancer may be much higher 
in individuals carrying particular functional selenoprotein SNPs such as those described 
below.  
 
Cytosolic glutathione peroxidase, GPx1 
Recent studies have reported a link between cancer risk and polymorphisms in the cytosolic 
glutathione peroxidase selenoprotein (GPx1) gene at Proline/Leucine 198 (P/L198).  
Possession of the L198 allele was associated with an increased risk of lung cancer in 
Caucasians but not among ethnic Chinese who do not appear to show this polymorphism 
(Ratnasinghe et al. 2000).  Possession of the L198 allele also conferred an increased risk of 
bladder cancer (see Table 6) and that risk was further raised in men that had one or two A 
alleles at codon 9 (apparently identical to codon 16, as described above) in exon 2 of MnSOD 
(Ichimura et al. 2004).  In the 213 bladder cancer patients, when compared with the P/P 
genotype, the P/L genotype was significantly associated with advanced tumour stage: OR 
2.58 (95% CI 1.07, 6.18, p = 0.034) for tumour stage T2-4 vs. Ta+1 (Ichimura et al. 2004).  
By contrast, in a case-control study of 399 cases of incident, invasive breast cancer and 372 
controls, no association between breast cancer and GPx1 L/P198 was found (Knight et al. 
2004).  However, the allele of GPx1 containing four GCG repeats was significantly 
associated with breast-cancer risk in pre-menopausal women (OR 1.55; 95% CI 1.04, 2.30, 
for carriers vs. non-carriers).  Importantly, GPx1 with the L-allele was less responsive to 
stimulation of its enzyme activity by Se supplementation than was GPx1 with the P-allele 
(Hu & Diamond, 2003).  
 
Studies showing selective loss of the P198-allele of the GPx1 gene during tumour 
development, as detected by loss of heterozygosity at this locus, implicate GPx1 in the risk 
and development of tumours.  In DNA from breast-cancer tissue, the L/L genotype was 
almost twice as common as in DNA from cancer-free individuals while the P/L genotype was 
underrepresented, indicating loss of heterozygosity at this locus in breast-tumour 
development (Hu & Diamond, 2003).  Similarly, DNA samples from head and neck tumours 
exhibited fewer heterozygotes and an increased frequency of the L/L genotype compared  
with DNA from the cancer-free population (Hu et al. 2004).   
 
15kDa selenoprotein, Sep15 
The 15kDa selenoprotein (Sep15) is expressed at high levels in normal liver and prostate but 
at reduced levels in the corresponding malignant organs (Behne et al. 1997).  It is located in 
the ER, tightly complexed to UDP-glucose:glycoprotein glucosyltransferase (UGTR), an 
enzyme involved in the quality control of protein folding (Korotkov et al. 2001).  (This may 
be of interest as some forms of Se appear to activate ER stress-induced apoptosis as 
mentioned above.)  The Sep15 gene lies on chromosome 1p22.3 at a locus commonly deleted 
or mutated in human cancers (Kumaraswamy et al. 2000; Kryukov et al. 2003).    Two SNPs 
at positions 811 (C/T) and 1125 (G/A) that are in strong allelic association have been studied 
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in the 3′-UTR of the Sep15 gene: G/A1125 lies within a functional SECIS element 
(Kumaraswamy et al. 2000).   The T811-A1125 variant was more effective in supporting 
UGA readthrough than the C811-G1125 variant, but was less responsive to the addition of Se 
to the culture medium (Kumaraswamy et al. 2002; Hu et al. 2001).  Thus the identity of the 
nucleotides at 811 and 1125 influences the function of the Sep15 SECIS element in a Se-
dependent manner (Kumaraswamy et al. 2000).  Individuals possessing one or other of these 
haplotypes may therefore differ in the efficiency with which they can make Sep15 and in how 
well they can use dietary Se.  
 
The frequency of the T811/A1125 haplotype is 0.25 in Caucasians and 0.57 in African 
Americans, who have a higher incidence of prostate cancer (Hu et al. 2001).  If lower levels 
of the Sep15 gene product predispose cells to malignant transformation in the human 
population, then those carrying a particular Sep15 gene polymorphism may be at a greater 
risk of cancer and might require significantly higher selenium intake for protection.  
Furthermore, among African Americans (but not Caucasians) there was a difference in allele 
frequencies in DNA from breast or head and neck tumours compared with DNA from cancer-
free controls.  The authors suggest that this difference is likely to be due largely to loss of 
heterozygosity at the Sep15 locus (Hu et al. 2001; Diwadkar-Navsariwala & Diamond, 2004).   
 
Additional evidence for an effect of this polymorphism on cancer risk comes from a study of 
Apostolou and colleagues (2004) which showed that the A1125 variant of Sep15 was less 
responsive to the apoptotic and growth-inhibitory effects of Se than the G1125 variant.  The 
Sep15 gene was shown to be downregulated in 60% of malignant-mesothelioma cell lines and 
tumour specimens in this study. 
 
Phospholipid glutathione peroxidase, GPx4 
GPx4 decreases lipid hydroperoxide levels.  By so doing, it inhibits the lipoxygenases that 
metabolise arachidonic acid to generate intermediates that mediate signals for increasing cell 
proliferation and inhibiting apoptosis (Kim & Milner, 2001).  In particular, it inhibits 5-
lipoxygenase and reduces the production of 5-hydroxyeicosatetraenoic acid (5-HETE), which 
is known to stimulate the proliferation of prostate-cancer cells (Ghosh & Myers 1998).  
Inhibition of 5-lipoxygenase has been shown to trigger massive apoptosis in human prostate 
cancer cells (Ghosh & Myers, 1998).  The C 718 allele of the GPx4 T/C718 SNP, which is 
close to the SECIS element in the 3'-UTR, has a frequency of 0.45 in Caucasians and is 
associated with increased levels of lymphocyte 5-lipoxygenase total products (Villette et al. 
2002).  Thus this polymorphism has functional consequences and may influence the 
production of 5-HETE and consequently the proliferation or apoptosis of prostate-cancer 
cells (Villette et al. 2002).  Two genetic studies (Wiklund et al. 2003; Hsieh et al. 2001) have 
shown linkage of the chromosome 19p13.3 region that contains the GPx4 gene to prostate 
cancer. 
 
Selenoprotein P, Sel-P  
SNPs have also been identified in selenoprotein P (Sel-P), a selenoprotein believed to be 
involved both in protection from reactive oxygen and nitrogen species and in the transport of 
selenium to tissues.  Normally, the Sel-P gene is highly expressed in prostatic epithelium but 
it is down-regulated in a subset of human prostate tumours, mouse tumours and prostate 
carcinoma cell lines (Calvo et al. 2002).  Calvo and colleagues suggest that reduced Sel-P 
synthesis occurs in a subset of patients resulting in loss of protection from oxidative stress.  
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Likelihood of simultaneous and consecutive effects at different cancer stages 
 
Given the breadth of evidence for the involvement of forms of Se in various anti-cancer 
processes, it is likely that Se acts at a number of stages in cancer development and by a 
number of different mechanisms which may operate simultaneously, or consecutively, 
involving both small-molecular-weight Se metabolites and selenoproteins.  Diwadkar-
Navsariwala and colleagues (2004) have proposed a model in which the likelihood of cancer 
development is linked to reduced levels of one or more protective selenoproteins resulting 
from:- (i) inadequate dietary Se intake and/or (ii) genetic polymorphisms that result in an 
increased Se requirement for selenoprotein synthesis and/or (iii) allelic loss of one or two 
gene copies during tumour development.   It may even be that exposure to some forms of Se 
provokes cellular stress, upregulating protective response systems (such as glutathione-S-
transferase) that reduce cancer risk (personal communication, Dr. Vadim Gladyshev, June 
2005).  Clearly we are far from a full understanding of this very complex area. 
  
 
 
Effect of Se on progression and metastasis 
 
There are a few indications that Se can have an effect on cancer progression or metastasis: 
three examples follow.  (i) The effect of Se status on prostate cancer is greater for advanced 
disease (disease that has spread beyond the prostate) than for primary disease (Nomura et al. 
2000; Li et al. 2004; van den Brandt et al. 2003) suggesting an inhibitory effect on tumour 
spread.  (ii) Angiogenesis is required for progression and metastasis.  It requires growth 
factors such as vascular endothelial growth factor (VEGF) and proteolytic degradation of the 
extracellular matrix by the family of matrix metalloproteinases (MMPs).  VEGF expression 
and protein levels were significantly lowered, as was the activity of MMPs, by methyl selenol 
precursors (Jiang et al. 1999, 2000, 2004) while selenite inhibited invasion of human 
fibrosarcoma cells by reducing the expression of MMP-2 and MMP-9 (Yoon et al. 2001).   
(iii) The tumour stage of bladder cancer is affected by GPx1 gentoype, giving indirect 
evidence that GPx1 is relevant to bladder cancer progression (Ichimura et al. 2004).   
 
 
 
Current and future Se-cancer projects 
 
The Selenium and Vitamin E Cancer Prevention Trial (SELECT), sponsored by the National 
Cancer Institute at a cost of $180m, is a Phase III, randomized, double-blind, placebo-
controlled trial designed to test the efficacy of Se (200 µg L-SeMet) and vitamin E (400 mg 
racaemic α-tocopherol), both alone and in combination, in the prevention of prostate cancer 
(Klein, 2004).  The target accrual of 32,400 male volunteers has been achieved and final 
results are expected in 2013.   
 
In Europe, the possibility of raising even a tenth of the sum made available in the US for 
SELECT for a similar-scale trial is remote.  However, European investigators are still hopeful 
that a sufficient sum can be raised to carry out a less-expensive web-based trial (PRECISE - 
PREvention of Cancer by Intervention with Selenium) with Se-yeast in Europe where Se 
intakes and status are so much lower.  As the strongest treatment effect in the NPC Trial was 
observed in subjects in the lowest tertile of plasma Se at baseline (Duffield-Lillico et al. 
 15
2002) this would greatly increase the chance of seeing an effect.  Equally importantly, it 
would eliminate the possibility of adverse effects in individuals of already-adequate Se status 
(120 µg/L or more) such as were seen in the top tertile in the NPC Trial (Duffield-Lillico et 
al. 2002).  Furthermore, women as well as men would be included in the European trial. 
 
Se-yeast is currently being used in further prostate cancer studies at the Arizona Cancer 
Center at doses of 200-800 µg/d, viz. the Negative Biopsy Trial (Stratton et al. 2003a), the 
Preprostatectomy Trial (Marshall, 2001) and the Watchful Waiting Trial (Stratton et al. 
2003b).   
 
There has not yet been a human trial with SeMeSeCys though apparently preparation for such 
a study in humans by Ip and colleagues is underway (personal communication, Dr. Mary 
Reid, June 2005).  As SeMeSeCys is not a very good precursor for selenoproteins, the results 
of such a study would be very informative. 
 
My colleagues and I are investigating the effect of functional selenoprotein SNPs on prostate 
cancer risk using 1400 DNA samples from prostate cancer cases and 800 age- and location-
matched controls from the CAPS study in Sweden (Wiklund et al. 2003).  We are also 
extending our careful speciation work (Goenaga-Infante et al. 2004, 2005) to identify low 
molecular-weight Se species in body tissues and fluids and in Se-enriched yeast and plants.    
 
 
Will industry let us find the definitive answer? 
 
Much time has elapsed during which scientists have spent increasing amounts of time and 
effort in fund-raising for demanding and meticulous studies to clarify whether Se truly has an 
effect in reducing cancer risk.  Industry has already made up its mind and is not prepared to 
wait.  Apart from Se supplements which have been around for many years, we are now seeing 
a greater push towards Se-containing functional foods and fertilizers and the selection or 
breeding of high-Se crop varieties (Broadley et al. 2005).  The worry is that population-based 
studies will become increasingly difficult to carry out under these circumstances so that the 
answer on Se and cancer in populations may never be definitive unless a European-based trial 
can be prioritised. 
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Table 1: Some selenoproteins of particular relevance to cancer 
 
Selenoprotein Function 
 
Glutathione peroxidases  
(particularly GPx1, Cytosolic; 
GPx2, Gastrointestinal; 
GPx4, Phospholipid) 
Antioxidant enzymes: remove hydrogen peroxide, lipid and 
phospholipid hydroperoxides thereby maintaining membrane 
integrity, modulating eicosanoid synthesis, modifying 
inflammation and the likelihood of propagation of further 
oxidative damage to biomolecules (Spallholz et al. 1990; Diplock, 
1994; Sunde, 1997; Allan et al. 1999).  
15kDa Selenoprotein (Sep15) Associated with the endoplasmic reticulum: may be involved in 
the regulation of protein folding (Korotkov et al. 2001).  Gene 
located in a region often altered in human cancers (Hu et al. 
2001).  Expressed at high levels in normal liver and prostate but 
at reduced levels in the corresponding malignant organs: may 
protect prostate cells against development of carcinoma (Behne 
et al. 1997). 
Selenoprotein P (SelP) Found in plasma and associated with endothelial cells.  
Antioxidant and transport functions (Burk et al. 2003). Scavenger 
of peroxynitrite, particularly at the endothelium (Arteel et al. 
1999).  Is down-regulated in human tumours (Calvo et al. 2002).  
Thioredoxin reductases (TR1, 
TR2, TR3) 
NADPH reduction of thioredoxin and other substrates; reduction 
of nucleotides in DNA synthesis; regeneration of antioxidant 
systems; maintenance of the intracellular redox state, critical for 
cell viability and proliferation; regulation of gene expression by 
redox control of binding of transcription factors to DNA (Allan et 
al. 1999).  More highly expressed in cancer cells than in normal 
cells and its expression is repressed by p53 (Gladyshev et al. 
1998). 
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Table 2. Large prospective studies of prostate cancer/advanced prostate cancer using tissue 
indicators of exposure 
 
Study Population No. of 
cases 
Indicator  
of exposure 
Comparison 
High vs. low 
RR1 95% 
confidence 
interval 
P for 
trend 
 
 
Knekt et al. 
1990 
 
Finland 
General population 
 
51  
 
Serum 
 
Quintile  
 
1.15 
 
- 
 
0.71 
 
Yoshizawa et 
al. 1998 
 
USA Health 
professionals 
 
181 
 
Toenails 
 
Quintile  
 
0.352 
 
0.16-0.78* 
 
0.03 
 
Nomura et al. 
2000 
 
USA Hawaii 
Japanese ancestry 
Non smoker 
Ex-smoker 
Current smoker 
Localised disease 
Advanced disease 
 
249 
 
87 
86 
76 
120 
64 
 
Serum 
 
Quartile 
 
0.5  
 
0.8 
0.5 
0.2 
0.8 
0.32 
 
0.3-0.9* 
 
0.4-1.9 
0.2-1.1 
0.1-0.8 
0.4-1.8 
0.1-0.8 
 
0.02 
 
0.93 
0.03 
0.02 
0.76 
0.01 
 
Helzlsouer et 
al. 2000 
 
USA 
Washington County 
 
 
117  
 
 
Toenails 
 
 
Quintile 
 
 
0.58 
0.383 
 
 
0.29-1.18 
0.17-0.85* 
 
 
0.27 
0.12 
 
Goodman et 
al. 2001 
 
 
USA CARET Trial 
asbestos workers/ 
current/ex-smokers 
retinol/β-carotene 
arm 
placebo arm 
 
235 
 
 
111 
124 
 
Serum 
 
Quartile 
 
1.02 
 
 
0.75 
1.52 
 
0.7-1.6 
 
 
0.41-1.36 
0.78-2.79 
 
0.69 
 
 
0.40 
0.12 
 
Brooks et al. 
2001 
 
USA 
Baltimore 
 
52 
 
Plasma 
 
Quartile 
 
0.24 
 
0.08-0.77* 
 
0.01 
 
van den 
Brandt et al. 
2003 
 
Netherlands 
Cohort Study 
Never smoker 
Ex-smoker 
Current smoker 
Localised disease 
Advanced disease 
 
540 
 
72 
300 
168 
189 
183 
 
Toenails 
 
Quintile 
 
0.69  
 
1.19 
0.46 
0.97 
0.72 
0.622 
 
0.48-0.99* 
 
0.48-2.92 
0.27-0.79* 
0.42-2.22 
0.42-1.24 
0.37-1.05 
 
0.008 
 
 
 
 
0.043 
0.020 
 
Li et al. 
2004 
 
 
 
 
 
 
USA Physicians' 
Health Study 
Baseline PSA>4 
Baseline PSA<4 
Localised disease 
Advanced disease 
 
586 
 
228 
293 
348 
171 
 
 
Plasma 
 
Quintile 
 
0.78  
 
0.49 
0.77 
0.97 
0.522 
 
0.54-1.13 
 
0.28-0.86* 
0.48-1.22 
0.64-1.49 
0.28-0.98* 
 
0.16 
 
0.002 
0.59 
0.91 
<0.05 
*denotes statistically-significant effect  
1RR relative risk for highest versus lowest category      
2Advanced disease 
3Adjusted for BMI at age 21, education and hours since last meal 
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Table 3. Meta-analysis of existing epidemiological evidence 
from 16 studies of Se and lung cancer (Zhuo et al. 2004)  
 
 RR 
high vs. low Se exposure
95% CI 
All subjects 0.74 0.57, 0.97 
Low Se areas 0.72 0.45, 1.16 
High Se areas 0.86 0.61, 1.22 
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Table 4. NPC Trial: relative risk (RR) of cancer incidence and mortality in the Se-treated 
group compared to the placebo group, by follow-up period  
 
Cancer Follow-up until RR 95% CI P 
Dec 31 1993 0.50 0.31,  0.80 0.002 All sites Mortality 
Feb 1  1996 0.59 0.39,  0.89 0.008 
Dec 31 1993 0.63 0.47,  0.85 0.001 All sites Incidence 
Feb 1  1996 0.75 0.58,  0.98 0.03 
Dec 31 1993 0.54 0.30,  0.98 0.04 Lung Incidence 
Feb 1  1996 0.70 0.40,  1.21 0.18 
Dec 31 1993 0.42 0.18,  0.95 0.03 Colorectal Incidence 
Feb 1  1996 0.46 0.19,  1.08 0.055 
Dec 31 1993 0.37 0.18,  0.71 0.002 Prostate Incidence 
Feb 1  1996 0.51 0.29,  0.87 0.009 
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Table 5. Some cellular processes and molecular pathways that may be involved in the anti-cancer 
effect of selenium 
 
Anti-cancer processes or pathways Selected evidence for Se involvement 
Selenoenzyme mechanisms  
     Reduction of DNA damage 
 
  
     Reduction of oxidative stress  
 
 
     Reduction of inflammation: inflammation    
     promotes tumour growth (Caruso et al.  
     2004). 
 
Se intake or status affected DNA damage in both human and 
animal studies (see text, Karunasinghe et al. 2004; Kowalska 
et al. 2005;  Waters et al. 2005). 
Levels of dietary antioxidant vitamins and carotenoids and 
SNPs that affect antioxidant selenoproteins modify the effect 
of Se on cancer risk (see text for references). 
Selenoenzymes can reduce hydroperoxide intermediates in 
the cyclooxygenase and lipoxygenase pathways preventing 
the production of pro-inflammatory prostaglandins and 
leukotrienes (Rayman, 2000). 
Induction of Phase II conjugating enzymes: 
detoxify carcinogens and reduce DNA adduct 
formation 
Some selenocompounds e.g. methyl selenol, can upregulate 
phase II conjugating enzymes such as glutathione-S-
transferase (GST), increasing detoxification of carcinogens 
(Ip & Lisk 1997).  Carcinogen adducts were reduced in liver 
and mammary gland of rats fed Se-enriched garlic, 
mushrooms and selenite (Davis & Finley 2003).  
Enhancement of immune response: cytotoxic 
lymphocytes and natural-killer-cells are able to 
destroy tumour cells 
Se supplementation (sodium selenite) enhanced the immune 
response of volunteers and cancer patients by increasing the 
numbers of cytotoxic lymphocytes and natural-killer cells 
(Kiremidjian-Schumacher et al. 1994, 2000).  
Increase in tumour-supressor protein p53: 
inhibits proliferation, stimulates DNA repair 
and promotes apoptotic death by acting as a 
transcription factor for several genes, including 
the damage-inducible gadd genes  
 
SeMet can activate p53 through redox regulation of key p53 
cysteine residues.  Methyl seleninic acid and sodium selenite 
modulate p53 activity by phosphorylation (Smith et al. 2004). 
Selenodiglutathione also induces p53 (Lanfear et al. 1994). 
Se compounds induced specific patterns of expression of 
gadd genes (Kaeck et al. 1997). 
Inactivation of protein kinase C (PKC), a 
signaling receptor that plays a crucial role in 
tumour promotion by oxidants 
Selective inactivation of PKC results from reaction of its 
catalytic domain with selenometabolites such methyl 
seleninic acid (formed from membrane-bound methyl selenol 
and fatty acid hydroperoxides), inhibiting tumour promotion 
and cell growth (Gopalakrishna & Gumimeda, 2002). 
Alteration in DNA methylation: abnormal 
methylation patterns are associated with 
neoplasia and inactivation of tumour-
suppressor genes  
Se affects the extent of DNA methylation and the activity of 
DNA methyl transferase (Davis et al. 2000; Davis & Uthus, 
2003; Fiala et al. 1998).  
 
Blockage of the cell cycle: inhibits growth and 
may allow DNA repair to take place 
Methyl selenol precursors can induce cell cycle arrest without 
single-strand breaks and with or without caspase induction 
and p53 regulation (Davis & Finley 2003).  By contrast, 
selenite induces DNA single- and double-strand breaks, cell-
cycle arrest, reduction in DNA synthesis and cell death, 
predominantly by necrosis (Medina et al. 2001). 
Induction of apoptosis of cancer cells: 
generally involves the sequential activation of 
the caspases, a family of proteases capable of  
degrading cellular components 
Methyl selenol precursors induce DNA double-strand breaks 
and cell death by apoptosis (Medina et al. 2001) involving the 
caspase cascade (Unni et al. 2001; Wang et al. 2002; Davis 
& Finley, 2003).  
Inhibition of angiogenesis: new blood vessels 
are required for the growth and metastasis of 
tumours 
Methyl selenol reduced microvessel density in chemically-
induced rat mammary carcinomas (but not in normal tissue), 
the expression of vascular endothelial growth factor (VEGF) 
and matrix metalloproteinases (Jiang et al. 1999).  p38 MAPK 
may be a key upstream mediator for the methyl selenol-
specific induction of vascular endothelial caspase-dependent 
apoptosis (Jiang et al. 2004). 
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Table 6. Association of GPx proline/leucine 198 (P/L198) allele with cancer risk (odds ratio, OR) and 
modification of risk by MnSOD genotype 
 
 Cancer Tissue 
sampled 
SNP  
genotype 
OR (95% CI)  
compared to 
P/P 
Reference 
 Lung Blood P/L 
L/L 
1.8 (1.2, 2.8) 
2.3 (1.3, 3.8) 
D Ratnasinghe et 
al. 2000 
 Bladder Blood P/L 
+MnSOD V/A+A/A  
2.6 (1.5, 4.8) 
6.3 (1.3, 31.2) 
Y Ichimura et al. 
2004 
 Breast Blood P/L 
L/L 
0.9 (0.7, 1.2) 
0.8 (0.5, 1.3) 
J Knight et al. 
2004 
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Figure captions 
Figure 1 
Mean Se intake levels (µg/d) in different countries (Combs, 2001; Rayman 2004) and the 
range of Se intake believed to be required for optimal activity of plasma GPx (Thomson et al. 
1993, Duffield et al. 1999)   
 
Figure 2 
The metabolism of dietary forms of Se (adapted from Combs, 2001, and Rayman, 2004) 
